[ad_1]
Common readers know that we don’t get distracted or unnerved by dropping inventory costs. It’s pure to really feel a bit panicky. You understand how lots of our article titles on gene-sequencing shares final yr have been variations on: “XXX Inventory Plummets: Why We’re Not Leaping to Our Loss of life?” About 15% of our Nanalyze Disruptive Tech Portfolio is weighted in life sciences – and practically all of that’s linked to gene-sequencing shares. In the event you’re in it for the lengthy haul, you don’t bail until you’ve misplaced religion in your funding thesis. We nonetheless consider genomics and gene-sequencing applied sciences will probably be key drivers in areas like precision medication and longevity, particularly in monitoring and treating ailments resembling most cancers.
The market chief in next-generation sequencing, Illumina (ILMN), has appeared like something however that with its failed GRAIL acquisition final yr. A few opponents enjoying the lengthy sport with long-read sequencing (LRS) seem like gaining traction. Whereas we like Pacific Bioscie…
[ad_2]
Source link
